Repurposed drugs for COVID-19: threshold and proof requirements for trials

Mical Paul; Andre C. Kalil

doi:10.1016/j.cmi.2021.08.024

Repurposed drugs for COVID-19: threshold and proof requirements for trials

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	1716-1717
Number of pages	2
Journal	Clinical Microbiology and Infection
Volume	27
Issue number	12
DOIs	https://doi.org/10.1016/j.cmi.2021.08.024
State	Published - Dec 2021

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.cmi.2021.08.024

Cite this

@article{3aca754dbe064880b80485ddd805939b,

title = "Repurposed drugs for COVID-19: threshold and proof requirements for trials",

author = "Mical Paul and Kalil, {Andre C.}",

year = "2021",

month = dec,

doi = "10.1016/j.cmi.2021.08.024",

language = "English (US)",

volume = "27",

pages = "1716--1717",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "12",

}

TY - JOUR

T1 - Repurposed drugs for COVID-19

T2 - threshold and proof requirements for trials

AU - Paul, Mical

AU - Kalil, Andre C.

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85115107427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115107427&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2021.08.024

DO - 10.1016/j.cmi.2021.08.024

M3 - Editorial

C2 - 34508887

AN - SCOPUS:85115107427

SN - 1198-743X

VL - 27

SP - 1716

EP - 1717

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 12

ER -

Repurposed drugs for COVID-19: threshold and proof requirements for trials

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this